Thoratec Corporation
THOR, a world leader in device-based mechanical circulatory support
therapies to save, support and restore failing hearts, announced today that
the company has received approval from Japan's Ministry of Health, Labour and
Welfare to market HeartMate II® ^ as a Bridge-to-Transplantation therapy for
patients suffering from advanced heart failure.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in